Drug intelligence / Profile preview

ACT-541468 + citalopram

Development stage
Unknown
Lead developer
Idorsia
Modality
Small Molecules
Administration
Oral
01

Overview

**ACT-541468 + citalopram** is a combination of two pharmaceutical drugs: daridorexant (code name ACT-541468), a dual orexin receptor antagonist being developed for the treatment of insomnia, and citalopram, a selective serotonin reuptake inhibitor (SSRI) widely approved for the treatment of major depressive disorder and other psychiatric conditions. Daridorexant promotes sleep via antagonism of orexin receptors OX1R and OX2R, which regulate wakefulness, while citalopram increases serotonin activity in the CNS by inhibiting its reuptake, thereby exerting antidepressant and anxiolytic effects. Co-administration is under clinical evaluation for pharmacokinetic and pharmacodynamic safety and tolerability in healthy individuals, with minor interaction effects and safety confirmed for doses up to 50 mg daridorexant with citalopram[1][3].

Brand names
Celexa
Other names
daridorexantcitalopram
02

Targets

HCRTR1 (Orexin/hypocretin receptor type 1)HCRTR2 (Orexin/hypocretin receptor type 2)SERT allosteric site (Serotonin transporter allosteric site)

Beyond the preview

Go deeper on ACT-541468 + citalopram.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on ACT-541468 + citalopram.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call